Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.4K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epstein-Barr virus (EBV) infection causes human germinal center B cell-derived lymphomas in the absence of EBNA2 expression.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Early-life Wnt4 expressing colon stromal cells orchestrate lifelong mucosal homeostasis via BMP-driven iNKT cell imprinting.

Nature communications·2026
Same author

Integrating Epstein-Barr virus (EBV) status into diffuse large B cell lymphoma (DLBCL) genetics.

bioRxiv : the preprint server for biology·2026
Same author

Integrated Multiomic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer.

Cancer research·2026
Same author

SR2P: an efficient stacking method to predict protein abundance from gene expression in spatial transcriptomics data.

bioRxiv : the preprint server for biology·2026
Same author

Integrated Single-Cell and Spatial Analysis Reveals Context-Dependent Myeloid-T Cell Interactions in Response to Immune Checkpoint Blockade in Head and Neck Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Video

Updated: Jan 11, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.4K

CD8+ T-cell Antitumor Immunity via Human iNKT-DC Conjugates.

Dana C Baiu1, Kelsey A Smith1, Sarah A Ferguson1

  • 1Department of Medical Microbiology and Immunology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

Cancer Immunology Research
|November 14, 2025
PubMed
Summary

Invariant Natural Killer T (iNKT) cells paired with dendritic cells (DCs) form potent cellular immunotherapy complexes. These iNKT-DC complexes effectively activate CD8+ T cells and reduce aggressive B cell lymphoma tumors.

More Related Videos

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

7.4K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.5K

Related Experiment Videos

Last Updated: Jan 11, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.4K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

7.4K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.5K

Area of Science:

  • Immunology
  • Cell Biology
  • Cancer Research

Background:

  • Invariant Natural Killer T (iNKT) cells amplify immune responses by interacting with dendritic cells (DCs).
  • The precise mechanisms of iNKT cell adjuvancy are not fully understood.
  • Understanding iNKT-DC interactions is crucial for developing novel immunotherapies.

Purpose of the Study:

  • To investigate the formation and function of iNKT cell-DC complexes.
  • To evaluate the therapeutic potential of iNKT-DC complexes in cancer models.
  • To elucidate the molecular mechanisms underlying iNKT-DC mediated anti-tumor immunity.

Main Methods:

  • Formation and characterization of allogeneic CD4+ iNKT cell-monocyte-derived DC bi-cellular complexes.
  • Analysis of DC surface molecule expression and calcium signaling.
  • Assessment of CD8+ T cell activation by iNKT-DC complexes.
  • In vivo efficacy studies using a human B cell lymphoma xenograft model.
  • Evaluation of iNKT-DC complexes in Head and Neck Cancer patient-derived DCs.

Main Results:

  • Allogeneic CD4+ iNKT cells form stable complexes with monocyte-derived DCs, enhancing DC calcium signaling.
  • iNKT-DC complexes exhibit a distinct co-stimulatory profile, including elevated MHC class I, 4-1BBL, OX40L, and IL-15Rα on DCs, and CD70 on iNKT cells.
  • These complexes potently activate CD8+ T cells.
  • In vivo administration of iNKT-DC complexes led to significant tumor reduction, antigen-specific B cell clearance, and enhanced T cell responses in a lymphoma model.
  • iNKT-DC immunotherapy demonstrated efficacy in late-stage, immune checkpoint blockade-refractory tumors and showed promise with Head and Neck Cancer patient-derived DCs.

Conclusions:

  • Monocyte-derived DCs paired with allogeneic CD4+ iNKT cells form a potent cellular immunotherapy.
  • iNKT-DC complexes activate antigen-specific CD8+ T cell immunity, rejuvenating exhausted anti-tumor responses.
  • This approach holds significant potential for treating aggressive cancers, including B cell lymphoma and Head and Neck Cancer.